DunneEGFickCNIsbellJM, et al. The emerging role of immunotherapy in resectable non-small cell lung cancer. Ann Thorac Surg2024; 118: 119–129.
2.
FeldmanHSepesiBLeungCH, et al. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg2024; 167: 1444–1453.
3.
BottMJYangSCParkBJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg2019; 158: 269–276.
4.
BaekJOwenDHMerrittRE, et al. Minimally invasive lobectomy for residual primary tumors of advanced non-small-cell lung cancer after treatment with immune checkpoint inhibitors: case series and clinical considerations. Clin Lung Cancer2020; 21: e265–e269.
